Nycomed's Omniscan approved in Japan
Hafslund Nycomed's Omniscan MRI contrast agent has been certifiedfor marketing in Japan, the Oslo, Norway, company reported thismonth. Nycomed said that Omniscan will be launched by DaiichiPharmaceutical, Nycomed's Japanese licensee, as soon as
Hafslund Nycomed's Omniscan MRI contrast agent has been certified
for marketing in Japan, the Oslo, Norway, company reported this
month. Nycomed said that Omniscan will be launched by Daiichi
Pharmaceutical, Nycomed's Japanese licensee, as soon as final
price approval is granted by Japanese authorities. Nycomed added
that it has submitted an application for marketing approval in
Japan for Visipaque, its third-generation x-ray contrast agent.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
